Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Shuji Ozaki, MD PhD, Takeshi Harada, MD PhD, Kengo Udaka, MD, Etsuko Sekimoto, MD PhD, Hironobu Shibata, MD PhD, Toshio Shigekiyo, MD PhD, Hikaru Yagi, MD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Masahiro Oura, MD, Shiro Fujii, MD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 5577.

https://doi.org/10.1182/blood-2018-99-115818

Published: 2018

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Masami Iwasa, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, PhD, Kumiko Kagawa, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Akishige Ikegame, MD, PhD, Daisuke Tsuji, PhD, Kohji Itoh, PhD, Masaki Ri, MD, PhD, Shinsuke Iida, MD, PhD, Yukimasa Shiotsu, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2012) 120 (21): 1839.

https://doi.org/10.1182/blood.V120.21.1839.1839

Published: 2012

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Hiroe Amou, PhD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, Ayako Nakano, MD, PhD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 1833.

https://doi.org/10.1182/blood.V118.21.1833.1833

Published: 2011

Journal Articles

Human Monoclonal Antibodies to TRAIL Receptors R1 and R2 Effectively Induce Apoptosis in Human Myeloma Cells.

Shuji Ozaki, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Takashi Ohshima, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Kazuhiro Motoki, PhD, Isao Ishida, PhD, Shiro Kataoka, PhD, Toshio Matsumoto, MD

Blood (2004) 104 (11): 3366.

https://doi.org/10.1182/blood.V104.11.3366.3366

Published: 2004

Journal Articles

Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.

Takashi Oshima, MD, Masahiro Abe, MD, Jin Asano, MD, Tomoko Hara, MD, Kenichi Kitazoe, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Shinsuke Kido, MD, Daisuke Inoue, MD, Toshio Matsumoto, MD

Blood (2004) 104 (11): 2356.

https://doi.org/10.1182/blood.V104.11.2356.2356

Published: 2004

Journal Articles

Generation of HM1.24-Specific Cytotoxic T Lymphocytes from Peripheral Blood Stem Cell Harvests of Patients with Multiple Myeloma.

Ali Jalili, Shuji Ozaki, MD, Tomoko Hara, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Takashi Ohshima, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Yasuhiko Nishioka, MD, Toshio Matsumoto, MD

Blood (2004) 104 (11): 1487.

https://doi.org/10.1182/blood.V104.11.1487.1487

Published: 2004

NARROW

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

Human Monoclonal Antibodies to TRAIL Receptors R1 and R2 Effectively Induce Apoptosis in Human Myeloma Cells.

Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.

Generation of HM1.24-Specific Cytotoxic T Lymphocytes from Peripheral Blood Stem Cell Harvests of Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

Human Monoclonal Antibodies to TRAIL Receptors R1 and R2 Effectively Induce Apoptosis in Human Myeloma Cells.

Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.

Generation of HM1.24-Specific Cytotoxic T Lymphocytes from Peripheral Blood Stem Cell Harvests of Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only